Open Access

REVIEW

SEMA MISIR^1,*, SERAP OZER YAMAN², NINA PETROVIĆ^3,4, CEREN SUMER⁵, CEYLAN HEPOKUR¹, YUKSEL ALIYAZICIOGLU²
Oncology Research, Vol.30, No.4, pp. 157-172, 2022, DOI:10.32604/or.2022.027547
Abstract Breast cancer (BC) is the most common heterogeneous disease in women and one of the leading causes of cancer-related death. Surgery, chemotherapy, radiotherapy, hormone, and targeted therapy are the gold standards for BC treatment. One of the significant challenges during the treatment of BC represents resistance to chemotherapeutics, resistance that severely limits the use and effectiveness of the drugs used for BC treatment. Therefore, it is essential to develop new strategies to improve therapeutic efficacy. Circular RNAs (circRNAs) are a large group of non-coding RNAs that covalently form closed circular loops by joining their 5′, and 3′; ends. Accumulating evidence… More >

View

1387

Download

908

Open Access

ARTICLE

DIEGO HERNANDEZ^1,*, CHIH-YUAN CHENG^1,2, KARLA HERNANDEZ-VILLAFUERTE¹, MICHAEL SCHLANDER^1,2
Oncology Research, Vol.30, No.4, pp. 173-185, 2022, DOI:10.32604/or.2022.027262
Abstract Lung cancer is the most common cancer type worldwide and has the highest and second highest mortality rate for men and women respectively in Germany. Yet, the role of comorbid illnesses in lung cancer patient prognosis is still debated. We analyzed administrative claims data from one of the largest statutory health insurance (SHI) funds in Germany, covering close to 9 million people (11% of the national population); observation period was from 2005 to 2019. Lung cancer patients and their concomitant diseases were identified by ICD-10-GM codes. Comorbidities were classified according to the Charlson Comorbidity Index (CCI). Incidence, comorbidity prevalence and… More >

View

1244

Download

493

Open Access

ARTICLE

HUAQING MO^#, JINGYI SHEN^#, YUXIAO ZHONG, ZENAN CHEN, TONG WU, YANYU LV^*, YANYAN XIE, YANRONG HAO^*
Oncology Research, Vol.30, No.4, pp. 187-199, 2022, DOI:10.32604/or.2022.027534
Abstract Nasopharyngeal carcinoma (NPC) is the most prevalent human primary malignancy of the head and neck, and the presence of vasculogenic mimicry (VM) renders anti-angiogenic therapy ineffective and poorly prognostic. However, the underlying mechanisms are unclear. In the present study, we used miR-940 silencing and overexpression for in vitro NPC cell EdU staining, wound healing assay and 3D cell culture assay, and in vivo xenograft mouse model and VM formation to assess miR-940 function. We found that ectopic miR-940 expression reduced NPC cell proliferation, migration and VM, as well as tumorigenesis in vivo. By bioinformatic analysis, circMAN1A2 was identified as a… More >

View

990

Download

541

Like

1

Open Access

ARTICLE

YONGKANG SHI, JUN MA, KE CHEN, BIN CHEN^*
Oncology Research, Vol.30, No.4, pp. 201-210, 2022, DOI:10.32604/or.2022.027584
Abstract 5-Fluorouracil (5-FU) is a commonly used chemotherapeutic agent for various cancers. However, the drug resistance developed by tumor cells hinders the therapeutic effect. Konjac glucomannan (KGM) is indicated to sensitize 5-FU-resistant hepatocellular carcinoma (HCC) cells to 5-FU. In our study, we found that KGM or 5-FU treatment alone did not affect the malignant cell behaviors and endoplasmic reticulum (ER) stress of 5-FU-resistant HCC cells or HepG2/5-FU and Bel-7402/5-FU cells, while cotreatment with KGM and 5-FU significantly facilitated HCC cell apoptosis and ER stress and suppressed cell proliferation potential and migration abilities. Moreover, we explored the underlying mechanism by which KGM… More >

View

906

Download

562